Trauma-Wiederbelebung mit Vollblut oder Produkten der Gruppe O mit niedrigem Titer (TROOP)
The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.
The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.
The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35294
- University of Alabama at Birmingham, UAB Hospital
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90033
- Los Angeles County + University of Southern California (LAC + USC) Medical Center
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70112
- University Medical Center New Orleans LCMC Health
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- University of Maryland Medical Center
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
-
North Carolina
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Atrium Health Wake Forest Baptist
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45267
- University of Cincinnati Medical Center
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97239
- Oregon Health and Sciences University Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Penn Presbyterian Medical Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- University of Texas Health Science Center Houston
-
San Antonio, Texas, Vereinigte Staaten, 78229
- University of Texas Health San Antonio and University Health System
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Harborview Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Froedtert Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)
-
Patient taken to trauma center directly from scene
-
Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting
-
Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol
-
Traumatic injury with at least one of the following:
- Confirmed or suspected acute major bleeding
- Assessment of Blood Consumption (ABC) Score ≥2
Exclusion Criteria:
- Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
- Patients transferred from another hospital
- Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
- Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
- Moribund patients expected to die within 1 hour
- Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
- Patients with known "do not resuscitate" orders prior to randomization
- Patients who refuse the administration of blood products
- Individuals with a research "opt out" bracelet.
- Greater than 20% total body surface area (TBSA) burns
- Suspected inhalation injury victims
- Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: LTOWB
Participants randomized to receive (Low Titer O Whole Blood [LTOWB]) |
Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously. |
|
Aktiver Komparator: Components
Participants randomized to receive the component blood products. |
Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
6-hour Mortality
Zeitfenster: First 6 hours after randomization
|
Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant) |
First 6 hours after randomization
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
24-hour Mortality
Zeitfenster: First 24 hours after randomization
|
Participant vital status at 24-hours following randomization |
First 24 hours after randomization
|
|
Hospital/30-day Mortality
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Incidence of Pre-specified Complications
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Adjudicated Primary Cause of Death
Zeitfenster: 30-days post randomization
|
Primary cause of death as reviewed and determined by the study investigators (consensus) |
30-days post randomization
|
|
Length of Stay (Hospital and Intensive Care Unit)
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Number of hours hospitalized (includes both hospital and intensive care unit time) |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Hospital-, Ventilator- and Intensive Care Unit-free days
Zeitfenster: 30-days post randomization
|
Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit. |
30-days post randomization
|
|
Incidence of major surgical procedures
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
The proportion of participants undergoing major surgical procedures. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Time to hemostasis in those undergoing procedures with a hemostatic component
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Zeitfenster: First 24 hours after randomization
|
The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.) |
First 24 hours after randomization
|
|
Discharge destination
Zeitfenster: At hospital discharge or 30-days post randomization (whichever the earlier)
|
Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc. |
At hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Functional status
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
|
Patient's quality of life
Zeitfenster: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome. |
From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Mitarbeiter
Mitarbeiter
Ermittler
Ermittler
- Hauptermittler: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Meizoso JP, Cotton BA, Lawless RA, Kodadek LM, Lynde JM, Russell N, Gaspich J, Maung A, Anderson C, Reynolds JM, Haines KL, Kasotakis G, Freeman JJ. Whole blood resuscitation for injured patients requiring transfusion: A systematic review, meta-analysis, and practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg. 2024 Sep 1;97(3):460-470. doi: 10.1097/TA.0000000000004327. Epub 2024 Mar 27.
- Jansen JO, Pedroza C, Novelo LL, Hao T, DeWildt GR, Coton CF, Mansoor K, Stephens SW, Marques MB, Stubbs JR, Richter JR, Wang HE, Holcomb JB, DeSantis SM. Trauma resuscitation with Low-Titer Group O Whole Blood Or Products: study protocol for a randomized clinical trial (the TROOP trial). Trials. 2025 Aug 2;26(1):266. doi: 10.1186/s13063-025-08971-y.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- IRB-300010517
- 1UG3HL157401-01A1 (US NIH Stipendium/Vertrag)
- 1U24HL157310-01A1 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .